002630 — Orient Bio Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Orient Bio, fiscal year end - March 31st, KRW millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	26,276	28,819	28,005	29,398	29,754
Cost of Revenue
Gross Profit	9,014	9,824	9,584	7,197	5,184
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	31,668	27,566	28,651	32,474	33,886
Operating Profit	-5,392	1,253	-646	-3,076	-4,132
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3,361	-12,591	12,871	-13,195	-4,567
Provision for Income Taxes
Net Income After Taxes	-3,430	-12,424	12,871	-13,195	-4,567
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	34,198	-12,424	12,871	-13,195	-4,567
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	34,198	-12,424	12,871	-13,195	-4,567
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-40.2	-208	217	-223	-77
Dividends per Share